PAR 2.04% 24.0¢ paradigm biopharmaceuticals limited..

Ann: Consistent pain reduction and improvement in function data, page-97

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 838 Posts.
    lightbulb Created with Sketch. 339
    Hi CosmoRings,
    In short Morgans do not know what they are talking about. If you look at the studies it is just not the case. They should actually do some research before they dribble false information into the market.

    IPPS is not a majic bullet for everyone however if you listen to some of the people in this forum and the AFL footballers etc who tell their stories of being able to play competitive sport again, others who can walk again the proof lies there. I think the phase 3 studies will reaffirm the existing levels however we will also know alot more about the DMOD impacts of IPPS which leads to stopping or reversing the OA. This is where the real fun will begin IMO.

    PAR at present are trying to get though Phase 3 by picking a proven benchmark (based on completed studies) PAIN. I think they will expand these studies and much more work will be done on IPPS going forward to prove its DMOD.


 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.0¢
Change
-0.005(2.04%)
Mkt cap ! $83.98M
Open High Low Value Volume
25.0¢ 25.5¢ 24.0¢ $202.2K 814.1K

Buyers (Bids)

No. Vol. Price($)
5 181098 24.0¢
 

Sellers (Offers)

Price($) Vol. No.
25.0¢ 118621 5
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.